Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02826434 · ClinicalTrials.gov registry record · Phase 1

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 1
Development phase
22
Enrollment target
5
Study locations

NCT02826434: Active Phase 1 study of Breast Cancer, sponsored by Massachusetts General Hospital.

NCT02826434 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 22 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02826434, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
22 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study is studying the safety, tolerability, and immune response of these treatments. The names of the study interventions involved in this study are: * PVX-410 Vaccine * Durvalumab (MEDI4736)

Conditions Studied

Breast Cancer

Interventions

  • BIOLOGICAL Durvalumab
  • DRUG Hiltonol
  • BIOLOGICAL PVX-410

Study Locations (5)

Massachusetts

  • Massachusetts general Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston

Florida

  • Lee Moffitt Cancer Center and Research Institute - Tampa

New York

  • New York University School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2016-08-18
Est. Completion 2027-09
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02826434

The ClinicalTrials.gov registry entry for NCT02826434 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.

NCT02826434 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT02826434 about?

NCT02826434 is a clinical study titled "Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer". The purpose of this research study is to evaluate Immunotherapy with a peptide vaccine and Programmed Death Ligand 1 (PD-L1) inhibitor as a possible adjuvant treatment for Stage II or III Triple Negative Breast Cancer. This research study is studying the safety, tolerability, and immune response of ...

What is the current status of trial NCT02826434?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-08-18. Estimated completion is 2027-09.

What conditions does trial NCT02826434 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02826434?

The interventions under investigation include: Durvalumab (BIOLOGICAL), Hiltonol (DRUG), PVX-410 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02826434?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02826434 being conducted?

This trial has 5 study locations across Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.